Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18527091 | 0.81 | AGBL2 (0.42) | NTRK1KMT2AMEN1CHRNA7PKM | |
| SCHEMBL18538093 | 0.77 | PDE2A (0.34) | NTRK1MTNR1ACHRNA7SPRPTGDR2 | |
| SCHEMBL12616365 | 0.76 | ADRA2A (0.33) | NTRK1KMT2AMEN1LMNASPR | |
| SCHEMBL17145183 | 0.72 | PKMYT1 (0.37) | NTRK1CHRNA7SPR | |
| SCHEMBL4403649 | 0.72 | NOS3 (0.38) | MTNR1ACHRNA7BRD4 | |
| SCHEMBL20413789 | 0.72 | MTNR1A (0.41) | NTRK1MTNR1ACHRNA7PTGDR2BRD4 | |
| SCHEMBL20413788 | 0.70 | ALDH1A1 (0.42) | KMT2AMEN1MTNR1ALMNABRD4 | |
| SCHEMBL18359212 | 0.69 | LRRK2 (0.38) | KMT2AMEN1CHRNA7LMNABRD4 | |
| SCHEMBL17211632 | 0.69 | BRD4 (0.55) | MTNR1ABRD4 | |
| SCHEMBL31370721 | 0.69 | BRD4 (0.35) | MTNR1ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | NTRK1 1009/4885KMT2A 3358/4885MEN1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.